表紙:非抗菌性細菌治療市場 - 技術、市場、戦略、予測
市場調査レポート
商品コード
1250861

非抗菌性細菌治療市場 - 技術、市場、戦略、予測

Non-Antibiotic Bacterial Therapeutics - Technologies, Markets, Strategies & Forecasts

出版日: | 発行: Greystone Research Associates | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
非抗菌性細菌治療市場 - 技術、市場、戦略、予測
出版日: 2023年04月04日
発行: Greystone Research Associates
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の非抗菌性細菌治療市場について調査し、市場の概要とともに、市場のアンメットニーズ、技術動向、規制と基準、市場に参入する企業のプロファイルを提供しています。

目次

  • エグゼクティブサマリー
  • 抗生物質を超えた細菌治療
  • エグゼクティブサマリー
  • 市場力学
  • アンメットニーズ
  • スコープの定義
  • 最近の開発と抗生物質のイノベーションの必要性
  • 進化する情勢
  • 年齢に応じた抗生物質
  • 技術
  • 抗体
  • 抗生物質失活酵素
  • バクテリオファージ
  • 抗菌ペプチド
  • 抗菌ナノ粒子
  • アンチセンス療法/遺伝子サイレンシング
  • 膜ポンプ別細菌化合物の能動的排出
  • 多剤耐性排出ポンプの過剰発現
  • シデロフォア
  • 非抗生物質微生物療法- 治療法
  • 抗体
  • アエルシン(アリディス)
  • ジンプラバ/ベズロトクスマブ(メルク)
  • MEDI 3902(メディミューン)
  • 514G3(Xバイオテック)
  • リシン
  • ファージ
  • 抗菌ペプチド
  • デフェンシン
  • アレニシン(アデニウムバイオテック)
  • ムレパバジン(POL7080)(Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • 世界市場の規制と基準
  • 北米
  • 米国FDA
  • 米国疾病管理センター
  • 欧州
  • 欧州疾病予防管理センター
  • アジア
  • 中国疾病管理予防センター
  • 国立疾病管理センター
  • 企業プロファイル
目次

‘Non-antibiotic Bacterial Therapeutics ’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for non-antibiotic therapeutic substances that can treat bacterial infections that are resistant to many or most available antibiotics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Novel Approaches Creating New Opportunities in Bacterial Therapeutics

As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift in treatment options.

What You Will Learn:

  • What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
  • What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving demand for non-antibiotic bacterial treatments?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2028?
  • What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
  • What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic bacterial therapies.

Table of Contents

  • Executive Summary
  • Bacterial Therapeutics Beyond Antibiotics
  • Executive Summary
  • Market Dynamics
  • The Unmet Need
  • Defining the Scope
  • Recent Developments and the Need for Antibiotic Innovation
  • The Evolving Landscape
  • Age-appropriate Antibiotics
  • Technology
  • Antibodies
  • Antibiotic-deactivating Enzymes
  • Bacteriophages
  • Antimicrobial peptides
  • Antimicrobial Nanoparticles
  • Antisense therapy/gene silencing
  • Active extrusion of bacterial compounds by membrane pumps
  • Overexpression of Multidrug resistance efflux pumps
  • Siderophores
  • Non-antibiotic Microbial Therapeutics - Therapies
  • Antibodies
  • Aerucin (Aridis)
  • Zinplava/Bezlotoxumab (Merck)
  • MEDI 3902 (MedImmune)
  • 514G3 (XBiotech)
  • Lysins
  • Phages
  • Antimicrobial Peptides
  • Defensins
  • Arenicin (Adenium Biotech)
  • Murepavadin (POL7080) (Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • Global Market Regulations and Standards
  • North America
  • US FDA
  • US Centers for Disease Control
  • Europe
  • European Centre for Disease Prevention and Control
  • Asia
  • Chinese Center for Disease Control and Prevention
  • National Centre for Disease Control (India)
  • Company Profiles